Table 4.
Baseline characteristics stratified by loop diuretic dose change over 52 weeks of follow-up
| Baseline characteristic | Loop diuretic change group | P-value | ||
|---|---|---|---|---|
| Dose decrease (n = 113) | No change (n = 855) | Dose increase (n = 121) | ||
| Female sex, n (%) | 52 (46.0) | 438 (51.2) | 55 (45.5) | .90 |
| Age, years, n (%) | .07 | |||
| <65 | 33 (29.2) | 283 (33.1) | 33 (27.3) | |
| 65–79 | 63 (55.8) | 500 (58.5) | 71 (58.7) | |
| ≥80 | 17 (15.0) | 72 (8.4) | 17 (14.0) | |
| Race,an (%) | .10 | |||
| Asian | 5 (4.4) | 66 (7.7) | 2 (1.7) | |
| Black or African American | 2 (1.8) | 30 (3.5) | 3 (2.5) | |
| Other | 1 (0.9) | 2 (0.2) | 1 (0.8) | |
| White | 105 (92.9) | 757 (88.5) | 115 (95.0) | |
| Body weight, kg | 105.8 (92.0, 121.7) | 102.9 (91.0, 117.2) | 109.2 (94.0, 124.4) | .69 |
| BMI, kg/m2 | 37.6 (34.1, 42.9) | 38.0 (34.5, 42.5) | 38.5 (35.5, 43.3) | .23 |
| Waist circumference, cm | 122.0 (113.8, 130.3) | 119.0 (111.0, 128.5) | 123.0 (113.0, 133.0) | .52 |
| Systolic BP, mmHg | 130.0 (117.0, 142.5) | 134.0 (124.0, 144.0) | 135.0 (124.0, 144.0) | .046 |
| NYHA class, n (%) | <.001 | |||
| II | 71 (62.8) | 613 (71.7) | 65 (53.7) | |
| III | 42 (37.2) | 240 (28.1) | 56 (46.3) | |
| IV | 0 (0.0) | 2 (0.2) | 0 (0.0) | |
| LVEF, % | 55.0 (50.0, 60.0) | 57.0 (51.0, 60.0) | 55.0 (50.0, 60.0) | .95 |
| KCCQ-CSS, score | 57.3 (41.7, 71.9) | 60.4 (44.3, 72.9) | 51.0 (33.3, 69.3) | .18 |
| 6MWD, metres | 260.0 (196.4, 352.0) | 300.0 (233.0, 373.0) | 265.4 (188.9, 342.0) | .60 |
| CRP, mg/L | 3.8 (1.9, 9.4) | 3.5 (1.8, 7.6) | 3.8 (1.8, 8.1) | .90 |
| NT-proBNP, pg/mL | 575.1 (289.2, 1110.4) | 426.2 (225.8, 954.8) | 749.3 (288.4, 1257.6) | .43 |
| Comorbidities at screening, n (%) | ||||
| Hypertension | 96 (85.0) | 711 (83.2) | 104 (86.0) | .82 |
| Atrial fibrillation | 58 (51.3) | 375 (43.9) | 67 (55.4) | .48 |
| Obstructive sleep apnoea | 16 (14.2) | 71 (8.3) | 21 (17.4) | .36 |
| Coronary artery disease | 40 (35.4) | 341 (39.9) | 52 (43.0) | .24 |
| Diabetes | 40 (35.4) | 477 (55.8) | 69 (57.0) | .001 |
| Diabetes duration, years | 10.4 (4.4, 21.5) | 7.9 (4.1, 14.1) | 7.1 (3.6, 17.0) | .24 |
| Concomitant medications, n (%) | ||||
| Beta blockers | 14 (12.4) | 139 (16.3) | 14 (11.6) | .82 |
| SGLT2 inhibitors | 95 (84.1) | 692 (80.9) | 96 (79.3) | .36 |
| MRAs | 18 (15.9) | 175 (20.5) | 19 (15.7) | .93 |
| Thiazide diuretics | 49 (43.4) | 267 (31.2) | 47 (38.8) | .52 |
| ACE inhibitor/ARB (ARNi) | 93 (82.3) | 678 (79.3) | 85 (70.2) | .022 |
| ARNi | 8 (7.1) | 43 (5.0) | 6 (5.0) | .48 |
| Insulin and analogues | 8 (7.1) | 88 (10.3) | 24 (19.8) | .001 |
| Sulfonylureas | 9 (8.0) | 90 (10.5) | 6 (5.0) | .40 |
| DPP-4 inhibitors | 8 (7.1) | 72 (8.4) | 9 (7.4) | .93 |
Continuous variables are expressed as median (25th–75th percentile). P-values for continuous variables computed from Jonckheere–Terpstra trend test; Cochran–Armitage trend test for binary variables; and Cochran–Mantel–Haenszel test for multinomial variables.
aRace was reported by the investigator.